Gong Hong-Tao, Mu Li-Ying, Zhang Tong, Xu Xiu-Ying, Du Feng-He
Department of Cardiology, Beijing Tiantan Hospital, Capital University of Medical Science, People's Republic of China.
J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827205. doi: 10.1177/1470320319827205.
: This study aimed to investigate whether mononucleotide polymorphisms of the angiotensinogen gene at promoter were associated with the blood-pressure-lowering response to telmisartan treatment.
: After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day of telmisartan and then were followed up for eight weeks. The -6A/G and -20A/C polymorphisms of the angiotensinogen gene at promoter were determined through polymerase chain reaction and restriction fragment length polymorphsim analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after eight weeks of treatment.
: There were no significant differences between -6A/G, -20A/C polymorphisms of the angiotensinogen gene and blood pressure reductions after treatment, p>0.05.
: It is suggested that angiotensinogen-6 A/G and angiotensinogen-20 A/C polymorphisms were not associated with the antihypertensive response to telmisartan treatment in Chinese patients with hypertension.
本研究旨在调查血管紧张素原基因启动子区的单核苷酸多态性是否与替米沙坦治疗的降压反应相关。
经过为期两周的单盲安慰剂导入期后，148例轻至中度原发性高血压患者接受每日80毫克替米沙坦单药治疗，随后进行为期八周的随访。通过聚合酶链反应和限制性片段长度多态性分析确定血管紧张素原基因启动子区的-6A/G和-20A/C多态性。治疗八周后观察并评估这些多态性与血压变化之间的关系。
血管紧张素原基因的-6A/G、-20A/C多态性与治疗后的血压降低之间无显著差异，p>0.05。
提示血管紧张素原-6A/G和血管紧张素原-20A/C多态性与中国高血压患者对替米沙坦治疗的降压反应无关。
